Introduction {#Sec1}
============

It has been shown that iron and folate are of great importance for women of reproductive age. The availability of sufficient quantities of these micronutrients plays a critical role in pregnancy and fetal development. Inadequate intake levels of these micronutrients among young women has been documented in many developed countries \[[@CR1], [@CR2]\].

Low levels of iron and folate have been also found in the daily food rations of pregnant women, which is associated with an increased risk of anemia for the mother and of neural tube defects for the fetus \[[@CR2]--[@CR4]\]. The World Health Organization (WHO) has estimated that iron deficiency anemia (IDA) affects approximately 146.5 million young children and 234 million nonpregnant women in the world, and constitutes an enormous public health problem leading to high mortality, especially in developing countries \[[@CR3], [@CR4]\]. The most detrimental effects of IDA are immunological and neurological disorders, impairment of thermoregulation, cognitive dysfunction, fatigue, and inhibition of psychomotor development \[[@CR5]\]. Women are generally more vulnerable to Fe deficiency than men \[[@CR5], [@CR6]\]. Due to its harmful health effect, Fe deficiency undoubtedly requires effective treatment. Folate deficiency leads to impaired DNA synthesis and increased death of hematopoietic cells, eventually resulting in anemia due to ineffective erythropoiesis. Large quantities of iron are also required for hemoglobin synthesis \[[@CR7]\]. Since folate and iron are required for effective erythropoiesis, the World Health Organization (WHO) has recommended daily oral iron and folic acid supplementation as part of antenatal care, in order to reduce the risks of low birth weight, maternal anemia, and iron deficiency \[[@CR3], [@CR4]\].

Experts in gynecology and nutrition have emphasized the importance of FA and Fe supplementation among women of reproductive age. However, increasing the intake of nutrients or using supplements is not always effective \[[@CR8], [@CR9]\]; its effectiveness depends on factors that affect the bioavailability of minerals and vitamins, which include the food matrix (i.e., interactions with other nutrients that may increase or decrease the absorption of folate or Fe, such as vitamin C and phytates \[[@CR10]\]) and the functioning of body, which in turn depends partly on genotype and gut microbiota \[[@CR11]\]. Thus, the effects of adding folic acid to oral Fe supplementation, as well as its possible favorable or disadvantageous consequences, especially under conditions of Fe deficiency, remain unknown.

The aim of this study was to investigate the effect of oral Fe and folic acid administered together or separately on the liver, kidney, heart, spleen, and pancreas Fe content in rats with deficiencies of these micronutrients.

Material and Methods {#Sec2}
====================

Animals {#Sec3}
-------

A total of 150 8-week-old female Wistar rats purchased from AnimaLab (Germany) were used. The mean weight of the rats was 182.9 g. The animals were housed in stainless steel cages coated with metal-free enamel and kept under cycles of 12 h light and 12 h dark. Room temperature was maintained at 20 ± 1 °C with 5565% humidity. The animal procedures were approved by the local bioethics committee (approval no. 59/2016).

Experimental Design {#Sec4}
-------------------

The animals were adapted to laboratory conditions during the first 5 days. In the first stage of the experiment, the animals were randomly assigned to two groups, the first of which contained 120 rats and the second of which had 30 rats. The animals were fed a semisynthetic diet based on the AIN-93M diet \[[@CR12]\]. Rats in first group were fed an iron and folate deficit diet, while those in the second group were fed the standard diet (Fe contents: 56 mg/kg and folic acid contents: 2 mg/kg). In the deficit diet, no iron and folic acid were added to the mineral and vitamin mixture of the AIN-93M diet. All rats were provided ad libitum diet and distilled water for 28 days. After that time, in the second stage, the first group was randomly divided into four groups of 30 rats each. Group D continued to intake the deficit diet, group FE was fed a deficit diet with iron gluconate (150 mg Fe/kg diet), group FOL was fed a deficit diet with folate acid (6 mg/kg diet), and group FEFOL was fed a deficit diet with iron gluconate (150 mg Fe/kg diet) and folate acid (6 mg/kg diet). Group C was fed the standard diet. The intake of the diets was monitored daily.

After 2 days, and then after 10 days and 21 days of the experiment, ten animals of each group were anesthetized and killed by cardiac puncture (after 12 h of fasting).

The liver, kidney, heart, spleen, and pancreas were dissected, weighted, and stored at − 80 °C. The initial and final body weights were measured using electronic scale.

Determination of Iron and Morphological Parameters {#Sec5}
--------------------------------------------------

Iron concentration in serum was determined using a commercial kit (Thermo Scientific, Vantaa, Finland). The iron content of the diet and tissues was determined following digestion in 65%(w/w) spectra pure HNO~3~ (Merck) in the Microwave Digestion System (Speedwave XPERT microwave digestion system, Berghof, Eningen, Germany). Thereafter, the concentration of iron was measured using flame atomic absorption spectrometry (Atomic Absorption Spectrophotometer ZA3000, Hitachi, Tokyo, Japan). The accuracy of the method was verified using certified reference materials: Brown Bread BCR191 for the diet samples, Sigma-Aldrich and bovine liver-trace elements, NIST-1577C, CERT, for tissue samples. The accuracies proved to be 94% and 95.5%, respectively.

Whole-blood morphological analysis (hemoglobin (HB), hematocrit (HCT), red blood cells (RBC), and mean corpuscular volume (MCV)) was performed by a commercial laboratory with the use of SYSMEX XT-4000 (Synevo, Poznań, Poland).

Statistical Analysis {#Sec6}
--------------------

Detailed statistical analysis was performed using Statistica for Windows12.0. (StatSoft, Poland). The results were expressed as arithmetic means with standard errors. One-way analysis of variance (ANOVA), followed by a post-hoc Turkey's test, were used to compare the data between groups. Student's *t* test was used to compare the two selected groups (D and FOL, FE and FEFOL). A Pearson correlation test was carried out to calculate correlations coefficients. The significance was set to the *p* \< 0.05 level.

Results {#Sec7}
=======

The results of the study are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, and [6](#Tab6){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. The iron concentration measured in the diet samples are shown in Table [1](#Tab1){ref-type="table"}. The daily intake of diet was comparable between groups and the daily intake of iron was around three times higher in the supplemented group than in the control group (Table [2](#Tab2){ref-type="table"}), as assumed. Initial and final body weight did not differ between groups in any period of the experiment. A significant change in relative tissue weight was observed only on day 2 of the experiment. The relative weight of the liver in the FE group was markedly higher than in the FOL group, while the relative weight of the pancreas in the FE group was lower than in the C and FEFOL groups (Table [3](#Tab3){ref-type="table"}). The concentration of iron in serum was comparable between the groups throughout the experiment (Table [4](#Tab4){ref-type="table"}). Significant changes in hemoglobin concentration and hematocrit were observed after 21 days of supplementation with higher level in C and FEFOL groups and lower level in D and FOL groups (Table [5](#Tab5){ref-type="table"}). Markedly differences in MCV values were found in all stages of the experiment and the highest level was observed in C group and the lowest in FOL group. Interestingly, significant correlation between RBC and MCV (*r* = − 0.34) was found only on 21 days of supplementation. This correlation may explain significant changes in HCT with comparable amount of RBC between groups, indicating that a larger number of red blood cells was associated with their smaller volume. On day 2 of the intervention, we observed that the iron concentration in the liver leveled out in the supplemented groups FE and FEFOL (Table [6](#Tab6){ref-type="table"}). In the spleen, kidneys, and heart, the iron level remained lower than in the control group. Short-time supplementation led to the highest level of iron in the pancreas of the FE group and the lowest in the FEFOL group. By day 10 of supplementation, the highest level of iron in the liver was found in the FE group. In the spleen and kidneys, significantly higher levels of iron in were seen in the C, FE, and FEFOL groups than in the D and FOL groups. However, the spleen concentration of iron was markedly higher in the FE and C groups than in the FEFOL group. In the pancreas and heart, the level of iron was higher in the C group than in the other groups (Table [5](#Tab5){ref-type="table"}). For long-term supplementation, we observed significantly higher concentrations of iron in the liver, spleen, and kidneys of the control and supplemented groups than in groups D and FOL. However, liver and spleen iron levels were much higher in the FE group than in the C and FEFOL groups. The lowest pancreatic concentration of iron was seen in the FOL group, while the highest was seen in the C group.Table 1Content of iron (mean and standard deviation) in the dietsGroupFe mg/kg dietC56.02 ± 0.13D6.91 ± 0.24FE154.94 ± 1.59FOL6.89 ± 0.09FEFOL155.42 ± 4.52Table 2Daily intake of the diet and iron (mean and standard deviation) in ratsGroupDiet (g)Fe (mg)2 daysC19.72 ± 0.971.10 ± 0.05D20.30 ± 0.990.14 ± 0.00FE19.03 ± 0.602.95 ± 0.09FOL19.59 ± 0.690.13 ± 0.00FEFOL20.53 ± 0.723.19 ± 0.1110 daysC20.31 ± 0.861.14 ± 0.05D20.75 ± 0.810.14 ± 0.00FE19.54 ± 0.833.03 ± 0.13FOL19.92 ± 0.330.13 ± 0.00FEFOL20.28 ± 0.763.15 ± 0.1221 daysC19.91 ± 0.901.11 ± 0.05D20.18 ± 0.730.14 ± 0.00FE19.73 ± 0.613.06 ± 0.09FOL18.96 ± 1.010.13 ± 0.00FEFOL20.98 ± 0.763.16 ± 0.12Table 3Body weight (g) and relative weight of tissues (% body mass) (mean and standard deviation)GroupInitial body weight (g)Final body weight (g)Liver (%)Spleen (%)Pancreas (%)Kidneys (%)Heart (%)2 daysC182.1 ± 10.8260.9 ± 15.62.67 ± 0.19^ab^0.25 ± 0.040.38 ± 0.08^b^0.68 ± 0.050.36 ± 0.02D182.3 ± 10.3267.0 ± 17.22.69 ± 0.21^ab^0.23 ± 0.020.38 ± 0.05^ab^0.67 ± 0.050.34 ± 0.04FE182.1 ± 10.2259.3 ± 17.42.74 ± 0.39^b^0.25 ± 0.050.30 ± 0.06^a^0.67 ± 0.040.35 ± 0.03FOL182.2 ± 10.1262.7 ± 19.12.45 ± 0.25^a^0.22 ± 0.030.35 ± 0.04^ab^0.66 ± 0.040.34 ± 0.03FEFOL182.0 ± 10.3264.7 ± 15.22.60 ± 0.31^ab^0.25 ± 0.020.39 ± 0.07^b^0.69 ± 0.040.34 ± 0.0210 daysC183.0 ± 10.3274.7 ± 14.72.50 ± 0.240.23 ± 0.030.30 ± 0.070.64 ± 0.040.33 ± 0.04D182.8 ± 10.6278.9 ± 17.92.49 ± 0.200.22 ± 0.040.35 ± 0.050.63 ± 0.120.33 ± 0.02FE183.0 ± 10.6267.5 ± 17.22.36 ± 0.130.21 ± 0.040.35 ± 0.040.63 ± 0.020.32 ± 0.02FOL183.0 ± 10.3275.3 ± 10.72.44 ± 0.440.24 ± 0.030.35 ± 0.070.65 ± 0.050.33 ± 0.03FEFOL183.1 ± 10.4283.8 ± 22.12.34 ± 0.430.24 ± 0.030.36 ± 0.060.65 ± 0.050.34 ± 0.0321 daysC184.0 ± 13.5289.8 ± 23.52.55 ± 0.210.25 ± 0.020.38 ± 0.130.65 ± 0.040.35 ± 0.03D184.0 ± 13.8291.4 ± 19.52.51 ± 0.280.24 ± 0.030.34 ± 0.050.67 ± 0.050.37 ± 0.02FE183.7 ± 12.4288.8 ± 24.82.45 ± 0.190.22 ± 0.020.33 ± 0.040.65 ± 0.060.35 ± 0.03FOL183.6 ± 11.7286.1 ± 25.82.36 ± 0.480.21 ± 0.040.34 ± 0.040.63 ± 0.050.35 ± 0.02FEFOL183.8 ± 11.8285.7 ± 22.52.38 ± 0.130.25 ± 0.030.33 ± 0.060.60 ± 0.100.31 ± 0.08^a,b,c^Significant differences between groups; ANOVA and Tukey's testTable 4Concentration of iron (mean and standard deviation) in serum (μg/ml) in ratsStageCDFEFOLFEFOL2 days2.83 ± 0.732.41 ± 1.183.21 ± 0.722.24 ± 0.812.74 ± 0.8810 days2.40 ± 0.502.13 ± 0.752.50 ± 1.052.19 ± 0.692.20 ± 0.5321 days2.61 ± 0.842.19 ± 0.772.13 ± 0.661.65 ± 0.592.99 ± 0.65Table 5Concentration of morphological parameters in rats (mean and standard deviation)GroupHB (g/l)HCT (l/l)RBC (× 10^12^/l)MCV (fl)2 daysC152.00 ± 3.610.47 ± 0.038.00 ± 0.2461.88 ± 1.41^b^D146.25 ± 3.300.47 ± 0.027.80 ± 0.5359.23 ± 1.12^a^FE141.75 ± 4.570.46 ± 0.017.73 ± 0.3160.22 ± 1.56^ab^FOL147.50 ± 7.780.48 ± 0.038.05 ± 0.2358.75 ± 1.38^a^FEFOL148.50 ± 4.510.48 ± 0.018.04 ± 0.3659.48 ± 1.74^a^10 daysC151.00 ± 3.460.46 ± 0.027.97 ± 0.2761.92 ± 1.42^b^D146.25 ± 3.300.47 ± 0.017.80 ± 0.5359.23 ± 1.12^a^FE150.50 ± 5.200.47 ± 0.028.07 ± 0.2158.79 ± 0.93^a^FOL148.50 ± 2.120.47 ± 0.017.91 ± 0.2258.22 ± 1.30^a^FEFOL147.00 ± 4.240.46 ± 0.027.75 ± 0.2559.06 ± 1.96^a^21 daysC147.33 ± 3.7^b^0.48 ± 0.01^b^7.98 ± 0.2860.41 ± 1.69^b^D131.00 ± 6.68^a^0.43 ± 0.01^a^8.00 ± 0.4356.58 ± 4.31^a^FE143.50 ± 5.00^ab^0.44 ± 0.02^ab^7.90 ± 0.1657.19 ± 1.39^ab^FOL138.00 ± 9.90^ab^0.43 ± 0.03^a^7.73 ± 0.2156.35 ± 2.28^a^FEFOL150.75 ± 4.57^b^0.47 ± 0.02^ab^8.04 ± 0.3557.46 ± 2.11^ab^*HB* hemoglobin, *HCT* hematocrit, *RBC* red blood cells, *MCV* mean corpuscular volume^a,b,c^Significant differences between groups; ANOVA and Tukey's testTable 6Concentration of iron (μg/g d.m.) in tissues in rats (mean and standard deviation)GroupLiverSpleenPancreasKidneyHeart2 daysC849.57 ± 186.62^b^2332.88 ± 436.27^c^63.03 ± 8.10^b^250.84 ± 37.14^b^291.61 ± 38.47^b^D171.38 ± 21.53^a^716.51 ± 138.39^ab^54.82 ± 13.41^ab^155.02 ± 52.07^a^267.06 ± 44.58^ab^FE788.47 ± 79.86^b^1061.37 ± 362.10^b^96.15 ± 16.72^c^182.58 ± 22.99^a^261.89 ± 28.33^ab^FOL187.69±62.30^a^701.69 ± 126.22^ab^49.79 ± 17.87^ab^163.34 ± 12.05^a^227.47 ± 42.86^a^FEFOL711.32 ± 164.23^b^459.56 ± 91.72^a^38.83 ± 14.26^a^194.44 ± 28.54^a^280.41 ± 76.31^ab^10 daysC853.68 ± 136.73^b^2275.55 ± 573.84^c^82.75 ± 24.68^b^243.38 ± 33.86^b^347.92 ± 78.64^b^D144.81 ± 21.89^a^779.03 ± 213.42^a^53.14 ± 6.26^a^133.83 ± 17.52^a^275.40 ± 55.36^a^FE1948.84 ± 343.78^c^2176.46 ± 253.42^c^61.48 ± 15.44^ab^220.81 ± 27.80^b^270.65 ± 30.00^a^FOL146.04 ± 43.38^a^564.54 ± 83.76^a^42.77 ± 12.56^a^156.19 ± 16.29^a^277.75 ± 33.22^a^FEFOL1100.29 ± 369.30^b^1546.73 ± 218.26^b^50.19 ± 21.74^a^233.65 ± 23.94^b^280.96 ± 13.47^a^21 daysC981.49 ± 256.92^b^2759.40 ± 491.76^b^89.00 ± 18.61^c^263.95 ± 58.34^b^305.85 ± 41.51D165.66 ± 34.26^a^715.93 ± 121.25^a^64.78 ± 12.30^b^148.92 ± 13.34^a^262.28 ± 27.89FE2417.41 ± 680.73^d^3217.85 ± 307.84^c^67.04 ± 14.82^b^245.24 ± 21.14^b^303.28 ± 34.41FOL150.64 ± 28.31^a^673.94 ± 130.65^a^39.64 ± 7.69^a^146.94 ± 12.54^a^284.74 ± 54.55FEFOL1796.61 ± 389.38^c^2386.43 ± 375.42^b^54.11 ± 12.49^b^276.58 ± 16.25^b^294.11 ± 24.87^a,b,c^Significant differences between groups; ANOVA and Tukey's testFig. 1Significant differences between concentration of iron (mean and standard deviation) in tissues in FE and FEFOL groupsFig. 2Significant difference between iron concentration (mean and standard deviation) in tissues in D and FOL groups

We also compared the groups that differed by the amount of folic acid in the diet---that is, D with FOL and FE with FEFOL. We found that level of iron in the FEFOL group was significantly lower after 2 days in the pancreas, and after 10 and 21 days in the liver and spleen than in the FE group (Fig. [1](#Fig1){ref-type="fig"}). We also observed that the concentration in the FOL group was markedly lower in the spleen after 10 days and in pancreas after 10 and 21 days than in group D (Fig. [2](#Fig2){ref-type="fig"}).

Discussion {#Sec8}
==========

In this study, we found that folate added to the diet affects tissue iron concentration in rats deficient in these micronutrients under conditions of both moderate and long-term supplementation. To the best of our knowledge, this is the first study to present such results.

The other important funding of this study is that iron concentration in the liver in deficient rats leveled out after only 2 days of supplementation with iron alone; in the spleen, pancreas, and kidneys, leveling took somewhat longer, lasting 10 days. Supplementation of both iron and folic acid extended the time for iron to replenish in the liver and spleen. Moreover, we observed that folate in the diet deficient in iron decreased iron concentration in the spleen and pancreas.

Iron deficiency causes anemia by production of smaller, less hemoglobinized erythrocytes \[[@CR7]\], which was partly confirmed in this study, especially in groups D and FOL after 21 days of intervention. It seems that folic acid in deficient diet may improve erythropoietic activity and enhance iron utilization which may lead to iron redistribution from the liver and spleen to the erythropoietic process. However, in this study, we did not observed significant change in RBC between groups after supplementation in any stages. Hemoglobin concentration increased significantly only on 21 days in group FEFOL received iron with folic acid and this result with comparable amounts of RBC could indicate an increase in reticulocytes. Unfortunately, in this study we did not measured reticulocytes. Moreover, iron- and folate-deficient diet resulted in a decrease of MCV and only long-term supplementation improved MCV in FE and FEFOL groups. Administration of folic acid alone did not influence on MCV. Analysis of morphological parameters shows that folic acid may affect iron distribution and its utilization in rats; however, it appears that the obtained results also point to other mechanisms of folic acid effect on iron status.

Several studies have indicated that simultaneous supplementation of folic acid and iron does not improve iron status \[[@CR13]--[@CR15]\]. Srivastava et al. \[[@CR13]\] found that 3-month supplementation with folic acid and iron did not significantly alter hemoglobin or ferritin concentration in women in the second trimester of pregnancy. Ahamed et al. \[[@CR14]\] observed a slightly increase in hemoglobin and ferritin levels in pregnant women after 100 days of iron and folic acid supplementation, and their intervention did not reduce anemia in the study population. Serdula et al. \[[@CR15]\] and Belay et al. \[[@CR16]\] also observed a poor hemoglobin response in pregnant women after supplementation with iron and folic acid. The low level of compliance with folate and iron supplementation observed in some studies may be associated with folate and iron interactions. In this study, differences in iron contents between groups were seen only in tissues, and not in serum (the results were comparable). This can be explained by the maintenance of iron homeostasis in the blood while changes occurred within the distribution and storage of this microelement.

An important role in the regulation of iron homeostasis is played by the liver, especially by its regulation of hepcidin levels \[[@CR17]\]. It is worth noting that a significant influence of folate on iron concentration was observed after 10 days of supplementation in the liver, spleen, and pancreas. Our results indicate that folic acid may decrease the bioavailability and distribution of iron in the organism. Although we did not examine all these mechanisms in our study, we found that during supplementation no interaction between iron and folic acid occurs on the level of duodenal transporters (unpublished data). It is certain that the mechanism that relates folate to iron status requires further investigation. Recent data have shown that multiple micronutrient supplementation (MMS) containing iron and folic acid is superior to Fe and folic acid supplementation alone. MMS in pregnancy reduced the risk of low birth weight, preterm birth, and being born small for gestational age; it also reduced the risk of neonatal and infant mortality \[[@CR18]\].

Both efficiency and safety are important in iron supplementation \[[@CR1], [@CR19], [@CR20]\]. On the basis of our results, we can conclude that folate decreases the efficiency of iron supplementation. However, the iron--folate combination may be beneficial for safety reasons, especially with long-term supplementation. We observed a great increase in iron content in the liver after 10 and 21 days of iron supplementation alone. Folate in the diet inhibited iron overload in the liver. Increased Fe accumulation in soft tissues has been demonstrated to be detrimental to their function \[[@CR21]\]. Excess hepatic Fe storage has an effect on liver fibrosis, cirrhosis, liver dysfunction, and (in some cases) cancer \[[@CR22]\]. It has been shown that Fe-dependent liver damage is associated with Fe-catalyzed oxidative stress \[[@CR23]\]. Previous studies have found that oral iron supplementation improved iron status, but also increased oxidative stress, even in women with low iron stores \[[@CR24], [@CR25]\]. Interestingly, Tiwari et al. \[[@CR26]\] observed that although treatment with iron and folic acid has remarkable efficacy in terms of hemoglobin, it may also lead to impaired liver function in pregnant anemic women. It has recently been shown that folic acid ameliorates liver inflammatory processes \[[@CR27]\] and hepatic steatosis \[[@CR28]\]. It seems that liver damage may by exacerbated by low serum folic acid concentrations, although the mechanism of this process is unknown \[[@CR28]\]. This beneficial effect of folic acid is associated with its ability to regulate the transcription of genes related to hepatic oxidative stress \[[@CR29]\] and 5′ AMP-activated protein kinase (AMPK) activity \[[@CR30]\]. Folic acid may also have an impact on iron transporters in the liver, such as divalent metal-ion transporter-1 (DMT1) and ZRT/IRT-like protein 14 \[[@CR31]\]. Hyeyoung et al. noted in Fe-loaded rats that hepatic ZRT/IRT-like protein 14 is twice as abundant as in Fe-adequate animals. The same study also determined that DMT1 levels in livers are lower in Fe-overloaded rats and higher in Fe-deficient animals \[[@CR31]\].

This study has some limitations: First of all, we examined only one dose of iron and folate in the supplements and only one form of iron (iron gluconate). These data did not include other folic acid or iron status (such as ferritin and hepcidin) parameters. We did not assess the mechanism of interaction between iron and folic acid.

Conclusion {#Sec9}
==========

Folic acid affects iron status in female rats deficient in these micronutrients in moderate and long-term supplementation. Thus, the use of iron supplements in combination with folates should be considered in terms of its effectiveness and safety.
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